Twist Bioscience Corporation (BIT:1TWST)
Italy · Delayed Price · Currency is EUR | Market Cap | 8.95B +425.2% |
| Revenue (ttm) | 377.95M +19.2% |
| Net Income | -119.67M |
| EPS | -1.95 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 21 |
| Open | 169.40 |
| Previous Close | 176.80 |
| Day's Range | 169.40 - 172.70 |
| 52-Week Range | 21.70 - 177.40 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 13, 2026 |
About Twist Bioscience
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglo... [Read more]
Financial Performance
In fiscal year 2025, Twist Bioscience's revenue was $376.57 million, an increase of 20.32% compared to the previous year's $312.97 million. Losses were -$77.67 million, -62.79% less than in 2024.
Financial numbers in USD Financial StatementsNews
Twist Bioscience initiated with a Hold at Jefferies
Jefferies initiated coverage of Twist Bioscience (TWST) with a Hold rating and $150 price target Twist is a synthetic biology company that manufactures synthetic DNA and DNA-based products using propr...
Twist Bioscience price target raised to $215 from $112 at Barclays
Barclays raised the firm’s price target on Twist Bioscience (TWST) to $215 from $112 and keeps an Overweight rating on the shares. The firm adjusted targets in the life science…
Twist Bioscience falls -12.7%
Twist Bioscience (TWST) is down -12.7%, or -$26.00 to $179.00.
Twist Bioscience price target raised to $212 from $107 at Guggenheim
Guggenheim raised the firm’s price target on Twist Bioscience (TWST) to $212 from $107 and keeps a Buy rating on the shares. The firm adjusted its models and forecasts for…
The Top HealthTech Questions Landing on Our Desks
Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled th...
Twist Bioscience price target raised to $190 from $160 at Leerink
Leerink analyst Puneet Souda raised the firm’s price target on Twist Bioscience (TWST) to $190 from $160 and keeps an Outperform rating on the shares. The firm cites peer group…
Twist Bioscience rises 6.9%
Twist Bioscience (TWST) is up 6.9%, or $10.88 to $169.38.
Twist Bioscience price target raised to $160 from $120 at Leerink
Leerink analyst Puneet Souda raised the firm’s price target on Twist Bioscience (TWST) to $160 from $120 and keeps an Outperform rating on the shares. The firm’s meetings with Twist’s…
Twist Bioscience enters agreement with Lilly TuneLab
Twist Bioscience Corporation (TWST) announced an agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (LLY). Twist is a provider of antibody cha...
Twist Bioscience Joins Lilly TuneLab to Advance Antibody Drug Discovery
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced an agreement with Lilly TuneLab, a collaborative ...
Twist Bioscience says Anthropic pilot work factored in FY27 orders expectations
Emily Leproust, the co-founder and CEO of Twist, was asked while presenting at the Baird Global Healthcare Conference about Twist having recently been named an independent evaluator chosen to produce…
Twist Bioscience Transcript: 2026 Global Healthcare Conference
Miniaturized DNA synthesis technology is driving rapid growth, with expanding applications in diagnostics and therapeutics. AI-driven drug discovery and data services are key growth drivers, supported by strong customer demand and strategic partnerships. Profitability is targeted for Q4, with long-term plans for sustained high growth and margin expansion.
AI & Robotics in 2026: 16 Recent Developments for Investors
If AI and robotics suddenly feel like they are moving faster, August gave investors plenty of evidence that the pace really is accelerating. We saw longer-running agents, faster and cheaper inference,...
Twist Bioscience initiated with a Sell at BWS Financial
BWS Financial initiated coverage of Twist Bioscience (TWST) with a Sell rating and $45 price target Twist’s stock surge in August, driven by Anthropic’s protein design research, was “an evaluation…
Twist Bioscience to Present at Baird 2026 Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder...
Twist Bioscience initiated with a Neutral at UBS
UBS initiated coverage of Twist Bioscience (TWST) with a Neutral rating and $144 price target The firm initiated and resumed 25 life science and diagnostics tools companies. UBS views life…
Twist Bioscience price target raised to $115 from $85 at Piper Sandler
Piper Sandler raised the firm’s price target on Twist Bioscience (TWST) to $115 from $85 and keeps an Overweight rating on the shares. The firm cites a higher long-term revenue…
Twist Bioscience 3.125M share Spot Secondary priced at $96.00
The deal size was increased to $300M in common stock from $250M in common stock. Goldman Sachs, William Blair, Leerink and Guggenheim acted as joint book running managers for the…
Twist Bioscience Announces Pricing of Upsized $300.0 Million Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST) (“Twist”), a mid-cap growth and value biotech company, today announced the pricing of an upsized underwritten ...
Twist Bioscience announces $250M common stock offering
Twist Bioscience (TWST) Corporation announced the commencement of an underwritten public offering of $250M of shares of its common stock. All of the shares of common stock to be sold…
Twist Bioscience Announces Proposed Public Offering of $250.0 Million of Common Stock
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (Nasdaq: TWST) (“Twist”), a mid-cap growth and value biotech company, today announced the commencement of an underwritten pub...
Twist Bioscience announces inducement grants under Nasdaq listing rule
As required by the rules of the Nasdaq Stock Market, Twist Bioscience (TWST) announced that a total of 44,434 restricted stock units will be granted to 24 recently hired individuals,…
Twist Bioscience Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--As required by the rules of the Nasdaq Stock Market, Twist Bioscience Corporation (NASDAQ: TWST) (“Twist” or the “Company”), a mid-cap growth and value bi...
Twist Bioscience price target raised to $115 from $113 at Baird
Baird raised the firm’s price target on Twist Bioscience (TWST) to $115 from $113 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results.
Twist Bioscience Earnings Call Transcript: Q3 2026
Record Q3 revenue grew 23% year-over-year, driven by strong demand in AI-enabled drug discovery and diagnostics. Raised fiscal 2026 guidance, expecting 21% annual growth and adjusted EBITDA breakeven in Q4. Triple-digit AI order growth is projected to continue into 2027.